Involvement of Apoptosis Inhibitor of Macrophages in a Rat Hypertension Model with Nephrosclerosis: Possible Mechanisms of Action of Olmesartan and Azelnidipine-Reference-Cited by-同舟云学术

Involvement of Apoptosis Inhibitor of Macrophages in a Rat Hypertension Model with Nephrosclerosis: Possible Mechanisms of Action of Olmesartan and Azelnidipine

Published:2013 Issue:8 Volume:36 Page:1271-1277
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Uramatsu Tadashi¹²,Nishino Tomoya¹,Obata Yoko¹³,Sato Yohei⁴,Furusu Akira¹,Koji Takehiko⁵,Miyazaki Toru⁴,Kohno Shigeru¹

Affiliation:

1. Second Department of Internal Medicine, Nagasaki University School of Medicine

2. Division of Blood Purification, Nagasaki University Hospital

3. Medical Education Development Center, Nagasaki University Hospital

4. Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo

5. Department of Histology and Cell Biology, Nagasaki University Graduate School of Biomedical Sciences

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/36/8/36_b12-00965/_pdf

Reference42 articles.

1. 1) Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet, 365, 331–340 (2005).

2. 2) Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA, 298, 2038–2047 (2007).

3. 3) Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 351, 1296–1305 (2004).

4. 4) Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int., 68, 228–236 (2005).

5. 5) Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J. Am. Soc. Nephrol., 12, 659–666 (2001).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD5L up-regulates the TGF-β signaling pathway and promotes renal fibrosis;Life Sciences;2024-10

2. The effects of apoptosis inhibitor of macrophage in kidney diseases;European Journal of Medical Research;2024-01-04

3. Cd5l Up-Regulate the Tgf-Β Signaling Pathway and Promote Renal Fibrosis;2024

4. Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease;Life Sciences;2023-08

5. Potential Impacts of Hydralazine as a Novel Antioxidant on Cardiovascular and Renal Disease—Beyond Vasodilation and Blood Pressure Lowering;Antioxidants;2022-11-11